Cellular transcriptomics and m6A epigenomics studies of WW-24 anti-tumour treatment
WW-24, when encapsulated in cytidinyl/peptidyl cationic lipid nanoparticles (DNCA/CLD), exhibits enhanced affinity and potent antitumour activity. A375 cells were treated with negative control/DNCA/CLD or WW-24/DNCA/CLD, along with an untreated group, with three biological replicates for each condition. Both high-throughput sequencing were performed by Shanghai OmicBio Biotechnology Co., Ltd.